SEC Form 4 · accession 0001214659-18-007840
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jamie Christensen
Officer — EVP, Chief Scientific Officer
Period of report
Dec 26, 2018
Accepted (ET)
Dec 28, 2018 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 26, 2018 | M | 5,169 | $17.41 | A | 8,789 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $17.41 | Dec 26, 2018 | M | 5,169 | D | — | May 20, 2024 | Common Stock | 5,169 | 13,767 | D |
Explanation of responses
- F11/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested.